What does a syringe cost?

Unit pricing for sterile and non-sterile disposable syringes ranges from $0.08 to $0.30 per syringe at hospital scale, depending on type, volume, material, and procurement model.

Medical syringes represent a high-volume, low-unit-cost commodity in hospital supply chains. The average global export price in 2024 was $252 per thousand units, representing an 11% increase from the previous year. For procurement officers managing syringe budgets, total annual spend depends less on unit price than on volume forecasts, GPO contract terms, and whether you're buying basic disposables or specialty devices. A 300-bed hospital ordering standard 3 mL Luer-lock syringes in bulk will pay far less per unit than a clinic ordering small cases of safety-engineered insulin syringes. This article outlines what moves syringe pricing and how to benchmark real costs.

What the typical range is

BD (Becton, Dickinson and Company): $18.99 per box of 100 for a conventional 3 mL Luer-Lok syringe with needle. That translates to approximately $0.19 per unit at manufacturer list price before GPO or volume discounts.

For unlocked (bulk-order) pricing available through third-party distributors, Bulk Case: 3mL Sterile Luer Lock Syringes: 24 Boxes of 100 (2400pcs) $219.00 , which equals roughly $0.09 per unit. Non-sterile variants run lower— BH Supplies Luer Lock Tip Syringes (No Needle) - Non Sterile, Bulk Packaging (3ML-2000) $150.00 , or $0.075 per unit for 2,000-unit orders.

Pricing spreads widen across volumes and features:

• General-purpose plastic syringes (no needle): $0.08–$0.15 per unit at 1,000+ unit orders
• Syringes with attached needle: $0.15–$0.25 per unit
• Safety-engineered syringes (retractable/shielded): $0.25–$0.50 per unit
• Insulin syringes (1 mL, fixed needle): $0.20–$0.40 per unit
• Prefilled syringes (medication pre-loaded): $0.50–$2.00+ per unit depending on drug

For 50-bed ASCs and small clinics ordering single cases (100–200 units), expect to pay 30–40% more per unit than hospital systems buying 500,000+ units annually.

What pushes price up — features, certifications, support tier

Safety mechanisms. By Type, the safety syringe segment has held the largest market share in 2024. The growth of the safety syringe is owing to benefits that safety bulbs offer outruns their duration of existence even at low cost over disposables, which further shifts the preference toward safety syringes. Retractable-needle and passive-shielded designs add $0.10–$0.30 per unit to raw material and assembly costs.

Material grade. Glass prefilled syringes command 2–3× the price of plastic disposables due to manufacturing precision, sterility assurance, and regulatory requirements for parenteral drug delivery. Mature markets like the US, Germany, and Japan exhibit demand for high-value, safety-engineered, and specialty syringes linked to advanced drug delivery systems.

ISO 13485 compliance. Regulatory convergence around ISO 13485 standards, effective in the United States from February 2026, is recalibrating competitive stakes by making quality systems a prerequisite for market access. The 2026 harmonization of U.S. quality-system regulations with ISO 13485 obliges every market entrant to upgrade documentation, risk management, and post-market surveillance protocols. Compliance costs elevate barriers to entry, incentivizing healthcare providers to narrow vendor rosters toward certified suppliers. Suppliers with audited, documented quality systems charge a compliance premium.

Sterilization method. Ethylene oxide (EO) sterilization costs more than gamma radiation; preserving heat-sensitive materials increases processing cycles. Low-dead-space designs (for insulin and biologics) require tighter tolerances and higher rejection rates in manufacturing.

Customization. Branded or modified syringe designs for specific drugs, volumes, or needle gauges incur setup and tooling fees, pushing MOQs (minimum order quantities) higher.

What pushes price down — refurbished, older generation, lease, GPO contracts

GPO membership. This manufacturer list price is the starting point for GPO negotiations on commodity-tier products. Most U.S. hospitals belong to at least one Group Purchasing Organization (GPO—Medline, Owens & Minor, Cardinal Health, etc.). GPO contracts typically achieve 20–35% discounts off list price through aggregate volume leverage. Verify your facility's GPO contract and that your ordering process routes through the preferred vendor to capture negotiated rates.

Large-volume framework agreements. Procurement models increasingly emphasize long-term framework agreements, stabilizing production schedules and enabling suppliers to leverage high-volume tooling. Standardized barrel volumes and luer-lock designs emerge as default specifications, further concentrating volume in dominant disposable categories. Committing to 6–12 months of forecasted volume (e.g., 500,000 units) unlocks better unit economics than spot purchases.

Older, stable designs. Standard 3 mL, 10 mL, 20 mL, and 30 mL Luer-lock syringes without safety features remain commodity items with mature manufacturing and minimal SKU proliferation. Avoid niche volumes or customized gauges unless clinically essential.

Distributor-direct purchasing. Smaller facilities can bypass traditional hospital distributors and order directly from warehouse suppliers (BH Supplies, Allegro Medical, Bound Tree) if not contracted through a GPO. Prices are often lower, but you forfeit rebate programs, consignment stock, and delivery guarantees.

Hidden costs — install, training, calibration, consumables, service contracts

Unlike large equipment, syringes have minimal hidden operational costs, but several factors inflate true spend:

Packaging and waste disposal. Individually wrapped syringes in rigid or soft packs add 15–20% to landed cost vs. bulk trays. Sharps container rental and medical waste incineration add $0.02–$0.05 per syringe disposed.

Storage and inventory turnover. Overstocking 12 months of supply ties up working capital and risks product expiration (syringes are sterile for 3–5 years depending on packaging). Under-stocking triggers emergency spot purchases at 50–100% premiums.

Compatibility verification. Switching vendors or syringe brands requires compatibility testing with your needle suppliers, IV tubing, and pre-filled drug cartridges. Budget staff time for validation.

Regulatory documentation. FDA 510(k) summaries, Material Safety Data Sheets (MSDS), and sterilization certificates must be maintained. Some suppliers charge for expedited documentation retrieval.

Training and waste reduction. Safety-engineered syringes reduce needlestick injuries (OSHA-reportable incidents), but staff retraining cycles and initial adoption resistance can delay ROI. Budget for competency verification.

How to negotiate — concrete tactics

1. Benchmark using GSA and VA pricing. Federal agencies publish GSA Schedule pricing for standard syringes. Review GSA eLibrary or VA Federal Supply Schedule contracts as reference points for your facility's negotiation baseline.

2. Lock in volume commitments. Offer a 12-month demand forecast in exchange for tiered pricing: e.g., $0.10 per unit for 500,000–999,999 units; $0.09 for 1,000,000+. Supplier confidence in volume justifies setup investment.

3. Consolidate SKUs. Reduce the number of syringe variants you stock. Limiting orders to 5–8 core sizes (1 mL, 3 mL, 10 mL, 20 mL, 30 mL, plus insulin and safety-engineered variants) cuts supplier complexity and opens volume discounts.

4. Request total-cost-of-ownership (TCO) analysis. Ask your GPO or supplier to model disposal costs, training time, and waste reduction over 12 months. Specialty syringes (safety-engineered) often reduce incident-related costs even at higher per-unit prices.

5. Standardize on ISO-compliant, multi-vendor designs. Luer-lock and slip-tip remain the industry standard. Insist that your preferred supplier commit to maintaining compatibility across needle gauges and IV connectors to avoid vendor lock-in.

6. Negotiate payment terms. Healthcare suppliers often offer 30–60 day terms. Pushing for net-60 or consignment-stock arrangements (you pay only for syringes used) improves cash flow and reduces inventory carrying costs.

When the price feels off — red flags

• Prices significantly below $0.08 per unit for sterile syringes. Suspect counterfeit, sub-standard imports, or non-sterile product misrepresented as sterile. FDA has issued warnings on non-compliant imports; sustained supply disruptions tied to sub-standard imports have prompted more than USD 400 million in domestic capacity expansions, led by BD's two-year USD 40 million program to scale Connecticut and Nebraska plants.

• No sterilization certificate or ISO 13485 audit documentation. Legitimate suppliers can produce third-party verification. Insist on it before placing large orders.

• Sudden price spikes from your incumbent supplier. Material-cost inflation, sterilization capacity constraints, or supply-chain disruptions may justify 5–10% increases. Larger jumps (15%+) signal potential vendor abuse. Solicit competing quotes immediately.

• MOQ (minimum order quantity) above your annual usage. If a supplier requires a 100,000-unit MOQ for a $0.10 price but your facility uses 40,000 units per year, the deal locks you into excess inventory. Negotiate flexible quarterly orders instead.

• Vague product specifications. Insist on syringe material (polypropylene), needle gauge/material, graduation accuracy (±10% or better), sterilization method (EO, gamma), and shelf life before signing POs.

• No emergency stock availability. Contract terms should include a clause for 48–72 hour emergency delivery of critical items (1 mL, 3 mL, 10 mL standard syringes) at agreed-upon premium rates (e.g., +20%), not unlimited markups.

Sources

IndexBox (2026). Syringes, Needles and Urinary Catheters Price in the United States. Data showing BD list pricing at $18.99 per box of 100 for 3 mL Luer-Lok syringes with needle.

IndexBox (February 2026). Global Syringe Market Report 2026. Average global export price of $252 per thousand units (2024), up 11% from prior year; note that pricing varies by type, region, and sales channel.

Mordor Intelligence (June 2025). Syringe Market Report. ISO 13485 regulatory harmonization effective February 2026; BD capacity expansion totaling $40 million over two years in Connecticut and Nebraska.

Precedence Research (2024–2025). Disposable Syringes Market. BD invested over $10 million in U.S. manufacturing in January 2024, with plans for $30 million additional investment in 2025; projected 40–50% domestic capacity increase by end of 2025.

Note: MedSource's syringe pricing database is still accruing institutional quote data from hospitals and GPOs. This article reflects publicly available manufacturer list prices, distributor retail pricing, and market research through May 2026. Actual institutional pricing will vary based on facility size, geography, contract status, and order timing. Check back as quote volumes accumulate.